Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
Evi KostenisMolecular, Cellular, and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany. kostenis@uni-bonn.de.ORCID 0000-0001-8284-5514
Jesus GomezaMolecular, Cellular, and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany.ORCID 0000-0002-2452-8016
Elke Miess-TannebergInstitute of Pharmacology and Toxicology, Jena University Hospital, Friedrich-Schiller-University of Jena, 07747, Jena, Germany.
Nina Kathleen BlumInstitute of Pharmacology and Toxicology, Jena University Hospital, Friedrich-Schiller-University of Jena, 07747, Jena, Germany.
Tobias BenkelMolecular, Cellular, and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115, Bonn, Germany.ORCID 0000-0001-8701-2706
Andy ChevignéImmuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), L-4354, Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-4768-6743
Carsten HoffmannInstitute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, Jena University Hospital, Friedrich Schiller University of Jena, 07745, Jena, Germany.ORCID 0000-0003-0884-9300
Peter KolbDepartment of Pharmaceutical Chemistry, Philipps-University of Marburg, 35032, Marburg, Germany.ORCID 0000-0003-4089-614X
Viacheslav NikolaevInstitute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.ORCID 0000-0002-7529-5179
Maria WaldhoerInterAx Biotech AG, 5234, Villigen, Switzerland.
Martyna SzpakowskaImmuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), L-4354, Esch-sur-Alzette, Luxembourg.ORCID 0000-0002-5659-8377
Asuka InoueGraduate School of Pharmaceutical Science, Tohoku University, Sendai, 980-8578, Japan.
Stefan SchulzInstitute of Pharmacology and Toxicology, Jena University Hospital, Friedrich-Schiller-University of Jena, 07747, Jena, Germany.ORCID 0000-0002-5997-8885
Jena University Hospital · DEUniversity of Bonn · DELuxembourg Institute of Health · LUPA Consulting Group · GBPhilipps University of Marburg · DETohoku University · JPUniversität Hamburg · DE
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Reply to: How carvedilol does not activate β · full record | OpenQuestion